Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.
Physicians Are Pessimistic About Future of Healthcare, Highlight Extent of Social Determinants
A majority of US physicians have a pessimistic view about the future of medicine, believe value-based payments won't improve quality of care or reduce costs, and treat patients with social conditions that impact their health.
NAACOS-Funded Study: ACOs Saved the Government $541.7M in 2013-2015
A new report contradicts CMS’ claim that the Medicare Shared Savings Program increased Medicare spending by $344 million from 2013 to 2015. The new analysis finds that accountable care organizations (ACOs) actually reduced federal spending by $542 million after accounting for shared savings payments earned.
CareMore Finds Success Using Lyft to Transport Medicare Beneficiaries to Appointments
Research has shown nonemergency medical transportation can be essential for patients in rural areas, as well as the poor, elderly, and chronically ill. In a Health Affairs blog post, authors from CareMore Health show how the company has found success with Lyft after a pilot program it ran in 2016.
Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells
Researchers at Baylor College of Medicine have found that preventing a mutated protein from leaving the nucleus and traveling to the cytoplasm of the cell can help inhibit the growth of leukemic cells in acute myeloid leukemia.
Prescription Drug Coverage Improved Survival for Patients With MM
Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.
Improved Access Not as Important as High-Quality Care in Preventing Deaths Globally
Access to care is not enough to improve care and prevent deaths; expansion of health coverage has to be paired with investments to create high-quality health systems, according to a study in The Lancet.
Security Check Trays Pose Highest Risk of Spreading Respiratory Viruses in Airports
Airports provide multiple sites of risk to contract respiratory viruses, with plastic security screening trays posing the highest potential risk, according to new research published in BMC Infectious Diseases.
Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma
Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
FDA Approves New Drug for Adults and Adolescents With Hemophilia A
A new long-acting treatment for hemophilia A has been approved for previously treated patients, aged 12 years and older. Bayer’s Jivi was also approved for on-demand treatment and the perioperative management of bleeding in the same population.
Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models
As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.
Percent of Employers Offering Health Coverage Increases for First Time Since 2008
New research from the Employee Benefit Research Institute has found that although there was some erosion in health insurance offered by employers after the implementation of the Affordable Care Act, the percentage of private-sector employers offering health benefits increased in 2017 for the first time since 2008.
Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers
A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.
Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.
Before Paying for Hospital-at-Home Programs, Clinical and Policy Issues Need to Be Addressed
In a new commentary in JAMA Internal Medicine, authors highlighted the results of the hospital-at-home (HaH) program at Mount Sinai Health System that resulted in the Physician-Focused Payment Model Technical Advisory Committee recommending full implementation of the bundled HaH program, as well as clinical and policy issues raised by the program.
Dose-Confirmation Study for Hemophilia B Gene Therapy Underway
The first patient has been treated in a phase 2b dose-confirmation study of AMT-061, an investigational gene therapy for the treatment of patients with severe and moderately severe hemophilia B. Once the dosing of AMT-061 is confirmed, the safety and efficacy of the therapy will be evaluated in the global phase 3 HOPE-B clinical trial.
MSSP Changes Present Opportunities, but Likely to Decrease Number of ACOs, NAACOS Says
The proposed Medicare Shared Savings Program rule has many sweeping changes that present a number new opportunities, but also challenges. In addition, the National Association of ACOs highlighted its concerns that the changes will decrease the number of ACOs and may discourage new entrants.
Substituting Brand-Name Combinations for Generics Could Have Saved Medicare $925 Million in 2016
Using lower-cost generic drugs that are as safe and effective as the brand-name versions could have saved more than $900 million in Medicare in 2016, according to research published in JAMA.
AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma
A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.